SK bioscience's GBP510 one step closer to being country's first vaccine
SK bioscience's Covid-19 vaccine candidate GBP510 demonstrated statistically meaningful results in Phase 3 trials, the company said Monday, bringing it one step closer to becoming the country's first homegrown Covid vaccine.